News

• 11.10.2009
  ACP's Investment Ironwood and Astellas Pharma Announce Japan Licensing Agreement for Linaclotide
• 11.02.2009
  ACP's Investment Beijing Goldenway Raises $11.7 Million
• 11.02.2009
  ACP's Investment Ironwood Pharmaceuticals and Forest Laboratories Announce Positive Linaclotide Results From Two Pivotal Phase 3 Trials
• 09.14.2009
  ACP's Investment Ironwood Appoints Thomas McCourt as Chief Commercial Officer and SVP of Marketing and Sales
• 09.14.2009
  David Ebersman Joins Board of Directors of ACP's Investment Ironwood
• 07.29.2009
  Divison of ACP's Investment Best Action Sports Launches Comprehensive Environmental Protection Initiative
• 05.31.2009
  ACP's Investment Ironwood Pharmaceuticals and Forest Laboratories Present Additional Positive Phase 2B Study Results for Linaclotide
• 05.04.2009
  ACP's Investment Ironwood Announces Linaclotide European Licensing Agreement With Almirall

• Arlon Capital Partners
  • Investments
  • Benefits of Private Capital
  • News
• Arlon Opportunities Investors
• Arlon Asset Management